Anaveon: Syncona : Anaveon announces publication of ANV419 Phase I data in The Journal for ImmunoTherapy of Cancer

(marketscreener.com) ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile Anaveon, a clinical stage, immuno-oncology company, today announced the publication of updated clinical data from the ongoing Phase I study of ANV419 in patients with advanced solid tumors in The Journal for ImmunoTherapy of Cancer . The...https://www.marketscreener.com/quote/stock/SYNCONA-LIMITED-11814171/news/Syncona-Anaveon-announces-publication-of-ANV419-Phase-I-data-in-The-Journal-for-ImmunoTherapy-of-C-45567799/?utm_medium=RSS&utm_content=20231214